| Protocol Number |
Title |
1999LS060
|
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia |
2001LS049
|
MT2001-02: Allogeneic Transplant for Hematological Malignancy |
2001LS058
|
MT2001-10 Allogeneic Bone Marrow Transplant Using Less Intensive Therapy |
2002LS032
|
MT1999-06: Vaccination with Tetanus Toxoid and Keyhold Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses |
2004LS006
|
MT2003-15 Use of Cyclophosphamide/Fludarabine to Promote in vivo Expansion of Donor Lymphocyte Infusion s(DLI) to Enhance Efficacy after Allogeneic Transplant |
2004LS034
|
MT2004-03: A Dose Escalation Study of CD4+ CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell (PBPC) Transplantation" MT2004-03: A Clinical Trial of Adult CD4+ CD25+ Regulatory T Cells in BMT Recipients |
2005LS023
|
MT2004-30: Dose Escalation of Total Marrow Irradiation Added To An Alkylator-Intense Conditioning Regimen For Patients with High Risk or Relapsed Solid Tumors |
2005LS036
|
MT2005-02: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen |
2005LS043
|
MT2005-10: Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen |
2005LS048
|
MT2004-24: Autologous Peripheral Blood Stem Cell Transplant for Patients with Lymphoma |
2006NT036
|
MT2007-16R Pilot Study of Vascular Function During Hematopoietic Cell Transplantation |
2007CG050
|
CALGB 50401: A randomized phase II trial of rituximab vs. lenalidomide (Revlimid, CC-5013) vs. rituximab + lenalidomide in recurrent follicular non-Hodgkin lymphoma (NHL) that is not rituximab-refractory |
2007LS064
|
MT2007-12: Allogeneic Natural Killer Cells with Rituximab in Patients with CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia ALSO -- Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis |
2007NT092
|
AHOD04B1 Hodgkin's Disease Banking Study |
2007NT123
|
2007-18R: Chronic GVHD Cohort Protocol |
2008CG045
|
CALGB 50501: A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (RevlimidTM, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma |
2008CG099
|
MT2008-30: A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) from Unrelated Donors in Patients with Hematologic Malignancies (2008-30) |
2008LS035
|
Phase I-II Trial of Genistein in Subjects Receiving Palliative External Beam Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life |
2008LS043
|
Phase II Trial of Bortezomib and Rituximab for Patients with Post Transplant Lymphoproliferative Disorders (PTLD) MT2008-05R |
2008LS112
|
A Therapeutic Trial of Decitabine (Dacogen) and Vorinostat (SAHA) in Combination with Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) MT2008-29R |
2008LS139
|
MT2008-38: A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies |
2009NTCG002
|
Pilot Study of Financial impact of Allogeneic Stem Cell Transplant |
Clinical Trials Help